Significant Tumor Inhibition of Trimethyl-152-[L-aspartyl]pheophorbide a in Tumor Photodynamic Therapy≠

IF 3.4 4区 医学 Q2 CHEMISTRY, MEDICINAL ChemMedChem Pub Date : 2025-03-12 DOI:10.1002/cmdc.202500087
Anita Benić, Akmaral Kussayeva, Ivana Antol, Mario Vazdar, Zlatko Brkljača, Dan-Ye Chen, Yi-Jia Yan, Ying-Hua Gao, Zhi-Long Chen, Davor Margetić
{"title":"Significant Tumor Inhibition of Trimethyl-152-[L-aspartyl]pheophorbide a in Tumor Photodynamic Therapy≠","authors":"Anita Benić,&nbsp;Akmaral Kussayeva,&nbsp;Ivana Antol,&nbsp;Mario Vazdar,&nbsp;Zlatko Brkljača,&nbsp;Dan-Ye Chen,&nbsp;Yi-Jia Yan,&nbsp;Ying-Hua Gao,&nbsp;Zhi-Long Chen,&nbsp;Davor Margetić","doi":"10.1002/cmdc.202500087","DOIUrl":null,"url":null,"abstract":"<p>A novel pheophorbide derivative, trimethyl-15<sup>2</sup>-[L-aspartyl]pheophorbide a was synthesised and investigated for anti-tumor activity. The prepared photosensitizer had good absorption in the phototherapeutic window and high ROS yields. It exhibited excellent phototoxicity higher than reference compound <i>m</i>-THPC when irradiated by 650 nm light in vitro, and obvious photodynamic anti-tumor effect in vivo. It causes cellular apoptosis or necrosis under laser irradiation and localizes in mitochondria, lysosome, and endoplasmic reticulum. The observed high efficacy was rationalized by efficient introduction into the blood by facile transfer through membranes, which is supported by molecular dynamics simulation studies. This work provides a new candidate photosensitizer for anti-cancer treatment.</p>","PeriodicalId":147,"journal":{"name":"ChemMedChem","volume":"20 10","pages":""},"PeriodicalIF":3.4000,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cmdc.202500087","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ChemMedChem","FirstCategoryId":"3","ListUrlMain":"https://chemistry-europe.onlinelibrary.wiley.com/doi/10.1002/cmdc.202500087","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

Abstract

A novel pheophorbide derivative, trimethyl-152-[L-aspartyl]pheophorbide a was synthesised and investigated for anti-tumor activity. The prepared photosensitizer had good absorption in the phototherapeutic window and high ROS yields. It exhibited excellent phototoxicity higher than reference compound m-THPC when irradiated by 650 nm light in vitro, and obvious photodynamic anti-tumor effect in vivo. It causes cellular apoptosis or necrosis under laser irradiation and localizes in mitochondria, lysosome, and endoplasmic reticulum. The observed high efficacy was rationalized by efficient introduction into the blood by facile transfer through membranes, which is supported by molecular dynamics simulation studies. This work provides a new candidate photosensitizer for anti-cancer treatment.

Abstract Image

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
三甲基-152-[l-天冬氨酸]酚a在肿瘤光动力治疗中的显著肿瘤抑制作用
合成了一种新型的硫代化合物三甲基-152-[l-天冬氨酸]硫代化合物A,并对其抗肿瘤活性进行了研究。所制备的光敏剂在光疗窗口内吸收良好,ROS产率高。在650 nm光照射下,其体外光毒性高于参比化合物m-THPC,在体内具有明显的光动力抗肿瘤作用。它在激光照射下引起细胞凋亡或坏死,并局限于线粒体、溶酶体和内质网。分子动力学模拟研究也证实了这种高效能的有效性。这项工作为抗癌治疗提供了一种新的候选光敏剂。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
ChemMedChem
ChemMedChem 医学-药学
CiteScore
6.70
自引率
2.90%
发文量
280
审稿时长
1 months
期刊介绍: Quality research. Outstanding publications. With an impact factor of 3.124 (2019), ChemMedChem is a top journal for research at the interface of chemistry, biology and medicine. It is published on behalf of Chemistry Europe, an association of 16 European chemical societies. ChemMedChem publishes primary as well as critical secondary and tertiary information from authors across and for the world. Its mission is to integrate the wide and flourishing field of medicinal and pharmaceutical sciences, ranging from drug design and discovery to drug development and delivery, from molecular modeling to combinatorial chemistry, from target validation to lead generation and ADMET studies. ChemMedChem typically covers topics on small molecules, therapeutic macromolecules, peptides, peptidomimetics, and aptamers, protein-drug conjugates, nucleic acid therapies, and beginning 2017, nanomedicine, particularly 1) targeted nanodelivery, 2) theranostic nanoparticles, and 3) nanodrugs. Contents ChemMedChem publishes an attractive mixture of: Full Papers and Communications Reviews and Minireviews Patent Reviews Highlights and Concepts Book and Multimedia Reviews.
期刊最新文献
A β-Glucuronidase-Responsive Albumin-Binding Prodrug of a Potent Focal Adhesion Kinase Inhibitor for Targeted Cancer Therapy. Monodentate Phosphine Modulation in Cyclometallated Platinum(II) Complexes for Antileishmanial, Antiviral, and Antitumor Applications. Investigating the Ligand-Binding Properties of N-arylbenzimidazoles as Novel Elastase Inhibitors. Evaluation of the Therapeutic Potential of Bioactive Materials Based on a Complex of Oxidovanadium(IV) and Exopolysaccharide Levan in a Model of Insulin Resistance in Mice. Front Cover: 5-Amino-7-Oxo-4,7-Dihydroazolo[1,5-a]pyrimidine-6-Carbonitriles: Synthesis and Study of Antitumor Effect In Vitro and In Silico (ChemMedChem 24/2025)
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1